UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033165
Receipt number R000037801
Scientific Title The relationship between level of lugol-staining of esophageal squamous epithelium (risk for incidence of esophageal squamous cell carcinoma (ESCC)) and impaired barrier function by acetaldehyde
Date of disclosure of the study information 2018/06/28
Last modified on 2018/06/28 13:39:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The relationship between level of lugol-staining of esophageal squamous epithelium (risk for incidence of esophageal squamous cell carcinoma (ESCC)) and impaired barrier function by acetaldehyde

Acronym

Esophageal acetaldehyde study

Scientific Title

The relationship between level of lugol-staining of esophageal squamous epithelium (risk for incidence of esophageal squamous cell carcinoma (ESCC)) and impaired barrier function by acetaldehyde

Scientific Title:Acronym

Esophageal acetaldehyde study

Region

Japan


Condition

Condition

Superficial ESCC

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To clarify the impact of esophageal mucosal barrier dysfunction by acetaldehyde on carcinogenesis of ESCC by comparing lugol-voiding lesion (LVL) and esophageal normal squamous epithelium (ENSE) in patients with ESCC

Basic objectives2

Others

Basic objectives -Others

Pathophysiology

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Esophageal mucosal barrier dysfunction in biopsy specimens of ENSC and LVL, which are exposed by acetaldehyde

Key secondary outcomes

1)Level of tight junction protein (TJP)/adhesion junction protein (AJP) in biopsy specimens of ENSE and LVL
2)Level of TJP/AJP RNA in biopsy specimens of ENSE and LVL
3)Oxidative stress marker, endogenous oxidase, and microRNA level in biopsy specimens of ENSE and LVL
4)The relationship between the epithelial barrier dysfunction and the amount of drinking and smoking or ALDH2/ADH1B polymorphism in biopsy specimens of ENSE and LVL


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Measuring esophageal mucosal barrier function in ENSE in patients with ESCC, using mini-Ussing chamber system

Interventions/Control_2

Measuring esophageal mucosal barrier function in LVL in patients with ESCC, using mini-Ussing chamber system

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)The patients with superficial ESCC who will receive endoscopic resection
(2)The patients with Eastern Cooperative Oncology Group performance status of 0-1
(3)The patients with aged 20 years or more
(4)The patients who agreed with informed consent

Key exclusion criteria

(1)Patients with regular use of NSAIDs, steroids, or immunosuppressive agents
(2)Patients with a history or a plan of surgery for esophagus, stomach, or duodenum
(3)Patients with a history of chemotherapy or radiation therapy against head and neck or esophageal cancers
(4)Patients with regular use of two or more anticoagulant or antiplatelet medication
(5)Patients with severe systemic diseases
(6)Pregnant or breastfeeding women
(7)Patients who participated in another studies with esophageal biopsies
(8)Patients with severe mental disease
(9)Patients who are judged inappropriate to entry the study

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoyuki Koike

Organization

Tohoku University Graduate School of Medicine

Division name

Division of Gastroenterology

Zip code


Address

1-1 Seiryo-machi, Aoba-ku, Sendai, Japan

TEL

022-717-7171

Email

tkoike@rd5.so-net.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Waku Hatta

Organization

Tohoku University Graduate School of Medicine

Division name

Division of Gastroenterology

Zip code


Address

1-1 Seiryo-machi, Aoba-ku, Sendai, Japan

TEL

022-717-7171

Homepage URL


Email

waku-style@festa.ocn.ne.jp


Sponsor or person

Institute

Division of Gastroenterology, Tohoku University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Division of Gastroenterology, Tohoku University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2018 Year 05 Month 24 Day

Date of IRB


Anticipated trial start date

2018 Year 06 Month 28 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 06 Month 27 Day

Last modified on

2018 Year 06 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037801


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name